Dark

Check out our API

PTEN
Patterson-UTI Energy Inc
stock NASDAQ

At Close

Jul 2, 2026 3:59:56 PM EDT

8.65USD+0.992%(+0.08)10,349,256

8.65Bid 8.67Ask 0.02Spread

Pre-market

Jul 2, 2026 9:23:30 AM EDT

8.57USD0.000%(0.00)1,881

After-hours

Jul 2, 2026 4:57:30 PM EDT

8.74USD+1.018%(+0.09)2,438,350

OverviewOptionsHistoricalExchangesShortsTrends

PTEN Reddit Mentions

Subreddits

Limit Labels Price

We have sentiment values and mention counts going back to 2017. The complete data set is available via the API.

Take me to the API

PTEN Specific Mentions

As of Jul 3, 2026 1:43:05 AM EDT (1 min. ago)

Includes all comments and posts. Mentions per user per ticker capped at one per hour.

41 days ago • u/Nelsons93 • r/pennystocks • gnpx_timeline_going_forward • 𝑺𝒕𝒐𝒄𝒌 𝑰𝒏𝒇𝒐 :stonk: • B

As of May 23, for anyone trying to keep up with what’s coming next, here’s the timeline the way I’m looking at it.
May 29–June 2: ASCO 2026
REQORSA biomarker data / TROP2 + PTEN angle. This is actual clinical biomarker data, not just early lab research.
June 18: Annual meeting / proxy vote
Worth watching because of the reverse split proposal and the other shareholder votes.
By June 30: Acclaim-1 & Acclaim-3 enrollment target window
Genprex has said they’re aiming for interim enrollment milestones in H1 2026.
July–December 2026: Bigger clinical window
Interim analyses are expected for Acclaim-1 and Acclaim-3.
GPX-002:
The FDA meeting already happened. Next up should be tox studies, manufacturing work, and more clarity on the IND path. No exact timing yet though.
The 10-Q also showed cash runway into H2 2027, so the company finally has some breathing room.
Runway is there.
Pipeline is moving.
Now management just has to deliver.
NFA
\#biotech #stocks #cancer #diabetes

sentiment -0.30

41 days ago • u/Nelsons93 • r/pennystocks • gnpx_timeline_going_forward • 𝑺𝒕𝒐𝒄𝒌 𝑰𝒏𝒇𝒐 :stonk: • B

As of May 23, for anyone trying to keep up with what’s coming next, here’s the timeline the way I’m looking at it.
May 29–June 2: ASCO 2026
REQORSA biomarker data / TROP2 + PTEN angle. This is actual clinical biomarker data, not just early lab research.
June 18: Annual meeting / proxy vote
Worth watching because of the reverse split proposal and the other shareholder votes.
By June 30: Acclaim-1 & Acclaim-3 enrollment target window
Genprex has said they’re aiming for interim enrollment milestones in H1 2026.
July–December 2026: Bigger clinical window
Interim analyses are expected for Acclaim-1 and Acclaim-3.
GPX-002:
The FDA meeting already happened. Next up should be tox studies, manufacturing work, and more clarity on the IND path. No exact timing yet though.
The 10-Q also showed cash runway into H2 2027, so the company finally has some breathing room.
Runway is there.
Pipeline is moving.
Now management just has to deliver.
NFA
\#biotech #stocks #cancer #diabetes

sentiment -0.30

Share